OTC Healthcare in the United Arab Emirates
Euromonitor International's OTC Healthcare in the United Arab Emirates market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Buy online to access strategic market analysis and an interactive statistical database of volume and value market sizes, company and brand shares, distribution and pricing data.
Tables: 86 | Publication date: Jul 2009
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouth care; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; OTC triptans; Vitamins and dietary supplements; Wound treatments
Executive summary
Steady growth in tough times, thanks to greater health awareness
As soon as the global financial crisis struck, the United Arab Emirates woke up to harsh repercussions, such as an outflow of resident expatriates late in 2008, waves of redundancies and others; all putting a downward pressure on consumer confidence. However, the OTC healthcare market managed to weather this dismal climate, and posted current value growth of 11% in 2008, thanks to rising health awareness in the country.
A new drug pricing system: exchange rates wreak havoc on drug prices
In light of the UAE dirham’s pegging to the US dollar and the appreciation of the Euro and other major currencies versus the dollar, the Ministry of Health revised the prices of 2,000 drugs with effect from October 2008. The review was implemented on all drugs purchased in Euros, Swiss francs, Swedish krone, Norwegian krone and Australian dollars; whereby 1,129 drugs out of the reviewed drugs were based in Euros.
In spite of multinationals’ dominance, Julphar becomes the largest company
OTC healthcare remained fragmented in 2008. The market is still dominated by multinationals, with Roche Holding AG, GlaxoSmithKline, Bayer AG and Boehringer Sohn all within the top five players. In 2008, domestic player Julphar Gulf Pharmaceuticals emerged as the largest NBO, with a value share of 7%; overtaking Roche Holding with less than a 7% value share. This was thanks to the government’s growing investment in the company, the expansion of its product portfolio, and more importantly, the company’s attractive pricing, especially at a time of lower consumer confidence.
Supermarkets/hypermarkets close the gap with chemists/pharmacies
Chemists/pharmacies continued to dominate OTC healthcare in 2008, with parapharmacies/drugstores being the other major distribution channel. Supermarkets/hypermarkets, however, broadened the range of OTC healthcare products on offer during the review period, with grocery retailers thus gaining share. This channel gained a significant presence in medicated skin care and vitamins and dietary supplements for the first time in the last two years of the review period. However, grocery retailers remained absent from most product categories, with the notable exception of wound treatments. Towards the end of the year, Carrefour and Ibn Sina (the country’s leading chain of pharmacies) joined forces and introduced a new retail concept to the UAE retailing environment; the pharmacy-in-hypermarket.
A healthy outlook in anticipation of discounted drug prices
Against a climate of lower consumer confidence and higher drug prices in 2008, there is still a positive outlook for OTC healthcare, thanks in part to anticipated price cuts. In November 2008, the Ministry of Health embarked on a series of meetings and negotiations with multinational pharmaceutical majors to discuss the possibility of trimming the prices of certain drugs by between 5% and 10%. The government’s initiative pertains to those drugs whose launch date exceeds five years. OTC healthcare is expected to post double-digit growth during the forecast period, with a CAGR of 10% in constant value terms.
Table of contents
OTC HEALTHCARE IN THE UNITED ARAB EMIRATES : MARKET INSIGHT
EXECUTIVE SUMMARY
Steady growth in tough times, thanks to greater health awareness
A new drug pricing system: exchange rates wreak havoc on drug prices
In spite of multinationals’ dominance, Julphar becomes the largest company
Supermarkets/hypermarkets close the gap with chemists/pharmacies
A healthy outlook in anticipation of discounted drug prices
MARKET INDICATORS
Table 1 Consumer Expenditure on Health Goods and Medical Services 2003-2008
Table 2 Life Expectancy at Birth 2003-2008
MARKET DATA
Table 3 Sales of OTC Healthcare by Sector: Value 2003-2008
Table 4 Sales of OTC Healthcare by Sector: % Value Growth 2003-2008
Table 5 OTC Healthcare Company Shares by Value 2004-2008
Table 6 OTC Healthcare Brand Shares by Value 2005-2008
Table 7 Sales of OTC Healthcare by Distribution Format: % Analysis 2003-2008
Table 8 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2008
Table 9 Forecast Sales of OTC Healthcare by Sector: Value 2008-2013
Table 10 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2008-2013
APPENDIX
OTC Registration and Classification
Vitamins & Dietary Supplements Registration and Classification
Generics
Switches
DEFINITIONS
Summary 1 Research Sources
ANALGESICS
Headlines
Trends
switches
Competitive Landscape
Prospects
Sector Data
Table 11 Sales of Analgesics by Subsector: Value 2003-2008
Table 12 Sales of Analgesics by Subsector: % Value Growth 2003-2008
Table 13 Herbal vs Standard Topical Analgesics 2003-2008
Table 14 Analgesics Company Shares by Value 2004-2008
Table 15 Analgesics Brand Shares by Value 2005-2008
Table 16 Forecast Sales of Analgesics by Subsector: Value 2008-2013
Table 17 Forecast Sales of Analgesics by Subsector: % Value Growth 2008-2013
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
Headlines
Trends
switches
Competitive Landscape
Prospects
Sector Data
Table 18 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2003-2008
Table 19 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2003-2008
Table 20 Sales of Decongestants by Type: Value 2003-2008
Table 21 Sales of Decongestants by Type: % Value Growth 2003-2008
Table 22 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: Value 2003-2008
Table 23 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: % Value Growth 2003-2008
Table 24 Herbal vs Standard Cough, Cold and Allergy (Hay Fever) Remedies 2003-2008
Table 25 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2004-2008
Table 26 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2005-2008
Table 27 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2008-2013
Table 28 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2008-2013
DIGESTIVE REMEDIES
Headlines
Trends
switches
Competitive Landscape
Prospects
Sector Data
Table 29 Sales of Digestive Remedies by Subsector: Value 2003-2008
Table 30 Sales of Digestive Remedies by Subsector: % Value Growth 2003-2008
Table 31 Herbal vs Standard Digestive Remedies 2003-2008
Table 32 Digestive Remedies Company Shares by Value 2004-2008
Table 33 Digestive Remedies Brand Shares by Value 2005-2008
Table 34 Forecast Sales of Digestive Remedies by Subsector: Value 2008-2013
Table 35 Forecast Sales of Digestive Remedies by Subsector: % Value Growth 2008-2013
MEDICATED SKIN CARE
Headlines
Trends
switches
Competitive Landscape
Prospects
Sector Data
Table 36 Sales of Medicated Skin Care by Subsector: Value 2003-2008
Table 37 Sales of Medicated Skin Care by Subsector: % Value Growth 2003-2008
Table 38 Herbal vs Standard Medicated Skin Care 2003-2008
Table 39 Medicated Skin Care Company Shares by Value 2004-2008
Table 40 Medicated Skin Care Brand Shares by Value 2005-2008
Table 41 Hair Loss Treatments Brand Shares by Value 2005-2008
Table 42 Forecast Sales of Medicated Skin Care by Subsector: Value 2008-2013
Table 43 Forecast Sales of Medicated Skin Care by Subsector: % Value Growth 2008-2013
VITAMINS AND DIETARY SUPPLEMENTS
Headlines
Trends
Competitive Landscape
Prospects
Sector Data
Summary 2 Dietary Supplements: Brand Ranking by Positioning 2008
Sector Data
Table 44 Sales of Vitamins and Dietary Supplements by Subsector: Value 2003-2008
Table 45 Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2003-2008
Table 46 Vitamins and Dietary Supplements Company Shares by Value 2004-2008
Table 47 Vitamins and Dietary Supplements Brand Shares by Value 2005-2008
Table 48 Vitamins Brand Shares by Value 2005-2008
Table 49 Dietary Supplements Brand Shares by Value 2005-2008
Table 50 Forecast Sales of Vitamins and Dietary Supplements by Subsector: Value 2008-2013
Table 51 Forecast Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2008-2013
NRT SMOKING CESSATION AIDS
Headlines
Trends
Switches
Competitive Landscape
Prospects
EYE CARE
Headlines
Sector Data
Table 52 Sales of Eye Care by Subsector: Value 2003-2008
Table 53 Sales of Eye Care by Subsector: % Value Growth 2003-2008
Table 54 Eye Care Company Shares by Value 2004-2008
Table 55 Eye Care Brand Shares by Value 2005-2008
Table 56 Forecast Sales of Eye Care by Subsector: Value 2008-2013
Table 57 Forecast Sales of Eye Care by Subsector: % Value Growth 2008-2013
WOUND TREATMENTS
Headlines
SECTOR DATA
Table 58 Sales of Wound Treatments by Subsector: Value 2003-2008
Table 59 Sales of Wound Treatments by Subsector: % Value Growth 2003-2008
Table 60 Wound Treatments Company Shares by Value 2004-2008
Table 61 Wound Treatments Brand Shares by Value 2005-2008
Table 62 Forecast Sales of Wound Treatments by Subsector: Value 2008-2013
Table 63 Forecast Sales of Wound Treatments by Subsector: % Value Growth 2008-2013
EAR CARE
Headlines
Sector Data
Table 64 Sales of Ear Care: Value 2003-2008
Table 65 Sales of Ear Care: % Value Growth 2003-2008
Table 66 Ear Care Company Shares by Value 2004-2008
Table 67 Ear Care Brand Shares by Value 2005-2008
Table 68 Forecast Sales of Ear Care: Value 2008-2013
Table 69 Forecast Sales of Ear Care: % Value Growth 2008-2013
ADULT MOUTH CARE
Headlines
SECTOR DATA
Table 70 Sales of Adult Mouth Care: Value 2003-2008
Table 71 Sales of Adult Mouth Care: % Value Growth 2003-2008
Table 72 Adult Mouth Care Company Shares by Value 2004-2008
Table 73 Adult Mouth Care Brand Shares by Value 2005-2008
Table 74 Forecast Sales of Adult Mouth Care: Value 2008-2013
Table 75 Forecast Sales of Adult Mouth Care: % Value Growth 2008-2013
CALMING AND SLEEPING
Headlines
EMERGENCY CONTRACEPTION
Headlines
OTC STATINS
Headlines
OTC OBESITY
Headlines
OTC TRIPTANS
Headlines
JULPHAR GULF PHARMACUETICALS
Strategic Direction
Key Facts
Summary 3 Julphar Gulf Pharmaceuticals: Key Facts
Summary 4 Julphar Gulf Pharmaceuticals: Operational Indicators
Company Background
Production
Summary 5 Julphar Gulf Pharmaceuticals: Production Statistics 2007
Summary 6 Julphar Gulf Pharmaceuticals: Production Statistics
Competitive Positioning
Summary 7 Julphar Gulf Pharmaceuticals: Competitive Position 2008
GULF DRUG ESTABLISHMENT
Strategic Direction
Key Facts
Summary 8 Gulf Drug Establishment: Key Facts
Summary 9 Gulf Drug Establishment: Operational Indicators
Company Background
Production
Competitive Positioning
ALPHAMED GROUP
Strategic Direction
Key Facts
Summary 10 Alphamed Group: Key Facts
Summary 11 Alphamed Group: Operational Indicators
Company Background